Can-Fite BioPharma reported that its Phase 2a Namodenoson study in advanced pancreatic ductal adenocarcinoma met the primary safety endpoint and delivered encouraging survival outcomes. While specific efficacy figures aren’t provided, the safety success plus supportive survival signals are a constructive clinical update that could support sentiment around the program.
Can-Fite BioPharma reported that its Phase 2a Namodenoson study in advanced pancreatic ductal adenocarcinoma met the primary safety endpoint and delivered encouraging survival outcomes. While specific efficacy figures aren’t provided, the safety success plus supportive survival signals are a constructive clinical update that could support sentiment around the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
